AstraZeneca Korea announced on the 14th that its immune anticancer drug "Imfinzi" has received additional approval from the Ministry of Food and Drug Safety for biliary tract cancer.

Imfinzi can be used as a combination therapy with Gemcitabine and Cisplatin in the primary treatment of patients with locally advanced or metastatic biliary tract cancer. It is the first indication of the first treatment of biliary tract cancer. The approval of this additional indication was based on a phase 3 TOPAZ-1 study that evaluated the effectiveness of lymphoid combination therapy compared to existing chemotherapy (Gemcitabine and Cisplatin) in 685 patients with local progressive or metastatic biliary tract cancer wh